BASKING RIDGE, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company...
Providence, RI, April 20, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated...
Fourth major clinical trial to select PharmAla Biotech as supplier in AustraliaVANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) --...
- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - -...
Phase 1 Thermography Study Quantitative Data Expected to Complement Patient Reported Outcome Data Collected in the Exploratory Phase 2b RESPOND...
WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company...
First Randomized, Placebo-Controlled Clinical Study to Report Successful E-Cigarette Cessation Benefit with Pharmacological Treatment Study Supports Potential Broad Utilization of...
RESEARCH TRIANGLE PARK, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading...
First patient dose in the Phase 1/2 clinical trial expected in mid-2023BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics,...
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader...
WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate...
Addition of new therapeutic expert reflects company’s commitment to drug development in hematologyDURHAM, N.C., April 19, 2023 (GLOBE NEWSWIRE) --...
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model...
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at...
Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6...
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral...
-- The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population -- -- First-in-human clinical trial...